# IBBIS

launched May 2024 as a free, open-source synthesis-screening package more robust against evasion attempts — including AI-generated sequences — than basic sequence-matching approaches, spun out of a US biosecurity nonprofit into an independent Swiss foundation.


Source: https://en.bioecon.ru/companies/ibbis/
Updated: 2026-08-15

- Country: Switzerland

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Affiliation | Incubated by the Nuclear Threat Initiative (NTI) \| bio | https://ibbis.bio/about/, https://www.longtermwiki.com/wiki/E536 |
| Research focus | DNA synthesis screening, biosecurity norms, and reducing emerging biological risks | https://ibbis.bio/about/, https://www.longtermwiki.com/wiki/E536 |
| Headquarters | Geneva, Switzerland | https://ibbis.bio/about/, https://www.longtermwiki.com/wiki/E536 |
| Grant | $3 million launch grant from Founders Pledge | https://www.longtermwiki.com/wiki/E536 |
| Principal staff | Piers Millett (Executive Director), Tessa Alexanian (Technical Lead), Rassin Lababidi (Technical Lead), Sophie Peresson (Technical Lead) | https://www.longtermwiki.com/wiki/E536 |
| Publications | Common Mechanism (commec) software package, various technical white papers and articles on biosecurity screening | https://ibbis.bio/our-work/common-mechanism/, https://ibbis.bio/our-work/common-mechanism/faq/, https://ibbis.bio/our-work/common-mechanism/get-started/ |

Independent sources: longtermwiki.com

## Technologies

- [DNA synthesis biosecurity screening](https://en.bioecon.ru/technology/dna-synthesis-biosecurity-screening/)